Clinical Trial

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

Completed Phase 2
View on ClinicalTrials.gov →
Summary
"The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults."
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-06; most recent amendment 2026-05-26.
Status change: Active, Not Recruiting → Completed 2026-05-26
Status change: Recruiting → Active, Not Recruiting 2025-11-12
Status change: Not Yet Recruiting → Recruiting 2025-10-09
Trial Details
NCT Number NCT07121192
Lead Sponsor GlaxoSmithKline
Conditions Influenza, Human
Enrollment 776 participants
Start Date 2025-08-25
Primary Completion 2026-05-11 (estimated)
Study Completion 2026-05-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-28